At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 899 enrolled
Drug / intervention
RO7234292 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients With Manifest Huntington's Disease
In Brief
A Phase 3 clinical trial evaluating RO7234292 and Placebo for Huntingtons Disease. Completed, enrolled 899 participants across 96 sites in 18 countries.
Detailed Summary
This study will evaluate the efficacy, safety, and biomarker effects of RO7234292 (RG6042) compared with placebo in participants with manifest Huntington's disease (HD)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHuntingtons Disease
CountriesArgentina, Australia, Austria, Canada, Chile, Denmark, France, Germany, Italy, Japan, Netherlands, New Zealand, Poland, Russia, Spain, Switzerland, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
First PostedDec 2018
Enrollment StartJan 2019
Primary CompletionMar 2022
TodayJul 2026
First PostedDec 3, 2018
Enrollment StartJan 23, 2019
Primary CompletionMar 24, 2022
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 7.6 years ago
Interventions
RO7234292drug
Intrathecal injection
Placebodrug
Intrathecal injection